Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity

(2020) Andrea Picchianti Diamanti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

(2020) James M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical and immunological features of severe and moderate coronavirus disease 2019

(2020) Guang Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Tocilizumab treatment in COVID-19: A single center experience

(2020) Pan Luo et al.   JOURNAL OF MEDICAL VIROLOGY

COVID‐19 pneumonia treated with Sarilumab: a clinical series of eight patients

(2020) Maurizio Benucci et al.   JOURNAL OF MEDICAL VIROLOGY

Effective treatment of severe COVID-19 patients with tocilizumab

(2020) Xiaoling Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

(2020) Jing Liu et al.   EBioMedicine

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

(2020) Emanuel Della-Torre et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients

(2020) Christina C. Price et al.   CHEST

Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation

(2020) Nicola Potere et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID‐19: a retrospective cohort study.

(2020) Johannes Eimer et al.   JOURNAL OF INTERNAL MEDICINE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

(2019) Lara L. Riegler et al.   Therapeutics and Clinical Risk Management

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis

(2019) Christine Xu et al.   CLINICAL PHARMACOKINETICS

Population pharmacokinetics of siltuximab: impact of disease state

(2019) Mina Nikanjam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma

(2013) Sheeba K. Thomas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects

(2011) S. Grange et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

(2010) Nicolas Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY